Modality
Small Molecule
MOA
CAR-T BCMA
Target
Nectin-4
Pathway
Complement
MigraineCRC
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
~Oct 2021
→ ~Jan 2023
Phase 2
Apr 2023
→ Jun 2031
Phase 2Current
NCT04872475
1,005 pts·Migraine
2024-04→2031-06·Terminated
NCT04498271
1,874 pts·CRC
2023-04→TBD·Not yet recruiting
2,879 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-06-235.2y awayPh3 Readout· Migraine
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Not yet…
P2/3
Termina…
Catalysts
Ph3 Readout
2031-06-23 · 5.2y away
Migraine
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04872475 | Phase 2/3 | Migraine | Terminated | 1005 | VA |
| NCT04498271 | Phase 2/3 | CRC | Not yet recr... | 1874 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| ION-3857 | Ionis | Preclinical | Nectin-4 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Semasacituzumab | Illumina | Phase 3 | Nectin-4 | |
| Elrainavolisib | Roivant Sciences | Preclinical | Nectin-4 |